For an accessible version of this Press Release, please visit www.tevapharm.com Q1 2025 Highlights: (1) Revised 2025 outlook now includes no contribution from the Japan BV after Q1 and continues to include a full year contribution from Teva API, as well as exclude the expected income from development milestone payments from Sanofi in connection with the Phase 3 ulcerative colitis and Crohn's Disease initiations for duvakitug. (2) This outlook is based on the existing tariff and trade environment as of May 7 ...

For questions regarding the event, please contact Teva's Investor Relations team at TevaIR@Tevapharm.com. A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 24 hours after the end of the live discussion. Cautionary Note Regarding Forward-Looking Statements Due to limited capacity, in-person attendance is by invitation only. Analysts and ...

The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. TEVA and Alvotech’s ALVO Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson & Johnson’s JNJ Stelara (ustekinumab).As of April 30, 2025, Selarsdi is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn’s disease, and ulcerative colitis.Also ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores. What a ...

Core Viewpoint - Teva Pharmaceutical Industries Ltd. is expected to report quarterly earnings of $0.47 per share, a decline of 2.1% year-over-year, with revenues projected at $3.97 billion, reflecting a 3.9% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 1.6% in the last 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts expect 'Revenue- COPAXONE- Total' to be $84.97 million, down 14.2% from the year-ago quarter [5]. - 'Revenue- API sales to third parties' is projected at $115.17 million, indicating a decrease of 10% year-over-year [5]. - 'Revenue- Other- Total' is estimated at $221.49 million, reflecting a significant decline of 30.4% from the previous year [5]. Geographic Revenue Insights - 'Geographic Revenue- International Markets' is expected to reach $615.76 million, a year-over-year increase of 3.1% [6]. - 'Geographic Revenue- United States' is projected at $1.87 billion, showing an 8.5% increase compared to the prior year [6]. - 'Geographic Revenue- United States- COPAXONE' is estimated at $32.38 million, up 7.9% from the year-ago quarter [6]. - 'Geographic Revenue- United States- BENDEKA / TREANDA' is forecasted to be $35.39 million, down 23.1% year-over-year [7]. - 'Geographic Revenue- United States- AUSTEDO' is expected to reach $360.74 million, reflecting a 27.9% increase from the previous year [7]. - 'Geographic Revenue- United States- Anda' is projected at $370.89 million, indicating a decrease of 2.7% year-over-year [8]. - 'Geographic Revenue- Europe- COPAXONE' is expected to be $43.68 million, down 23.4% from the year-ago quarter [8]. - 'Geographic Revenue- Europe- Respiratory products' is projected at $60.84 million, reflecting a decline of 7.8% year-over-year [9]. - 'Geographic Revenue- International Markets- Generic products' is expected to reach $487.47 million, indicating a 2.2% increase from the prior year [9]. Stock Performance - Over the past month, Teva shares have increased by 17.3%, outperforming the S&P 500 composite's 0.4% change [10]. - Teva holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [10].

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positiveEPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris® (eculizumab), making it one of the greatest cost-saving biosimilars to Soliris® in the U.S.Teva and Samsung Bioepis en ...

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatmentsAJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options1These efforts underscore Teva's dedication to expanding access to innovative neurosci ...

PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very ...

Core Insights - Teva Pharmaceuticals presented a survey study on patient and healthcare professional attitudes towards TEV-'749, a long-acting injectable formulation of olanzapine, at the 2025 Congress of the Schizophrenia International Research Society, showing high satisfaction rates among patients and healthcare providers [1][2][4] Group 1: Survey Findings - Over 92% of schizophrenia patients reported satisfaction with TEV-'749's initiation regimen, dosing schedule, and trial medication [4][12] - 87% of nurses and 72% of physicians expressed satisfaction with TEV-'749 [1][12] - A significant preference for subcutaneous (78.6%) over intramuscular injection (21.4%) was noted among patients, with needle size being a primary factor [5] Group 2: Clinical Context - TEV-'749 is being evaluated in the Phase 3 SOLARIS trial, which aims to assess its efficacy, safety, and tolerability as a long-acting injectable for schizophrenia [11][9] - The drug leverages SteadyTeq™, a proprietary technology for controlled release, which may mitigate the risk of Post-Injection Delirium/Sedation Syndrome (PDSS) associated with current treatments [9][2] Group 3: Healthcare Professional Insights - Healthcare professionals indicated that the post-injection monitoring period could present barriers to treatment, with over 90% of physicians and more than 66% of nurses acknowledging potential challenges [5][12] - A majority of participants preferred a simpler initiation regimen requiring only one injection, with 72.9% of patients and 90.9% of physicians favoring this approach [5][12] Group 4: Broader Implications - Teva's commitment to advancing treatment for schizophrenia is underscored by the positive feedback from the survey, which highlights the importance of patient and provider perspectives in drug development [2][4] - The findings from the survey and ongoing trials may influence future treatment protocols and patient adherence strategies in schizophrenia management [3][4]

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call w ...